Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corina is an innovative drug-device-combination therapy developed by Yipurun (Shanghai) Biotechnology Co., Ltd., a wholly-owned subsidiary of Puyi (Shanghai) Biotechnology Co., Ltd. It is made from non-degradable, medical-grade material and contains the active ingredient estradiol. Designed to conform to the shape of the female uterus, Corina acts as a physical barrier upon insertion and enables targeted delivery of estradiol to the endometrium. It continuously releases estradiol for up to 60 days post-procedure to promote endometrial growth and prevent re-adhesion. Corina has been approved in China for treating moderate-to-severe intrauterine adhesions (IUA) in patients undergoing transcervical resection of adhesions (TCRA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Corina Intrauterine Drug-Eluting System.